The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

Early‐phase clinical trials using oral inhibitors of MEK, the mitogen‐activated protein kinase kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1)‐associated tumors, particularly progressive low‐grade gliomas and plexiform neurofibromas. Given this potential of MEK inh...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Symptom Management and Supportive Care
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356675/
https://ncbi.nlm.nih.gov/pubmed/32272491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0069
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items